( y assigned to either the CAELYX or the ...)Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer,Health

y assigned to either the CAELYX or the observation arm. The incidence of nausea/vomiting and alopecia were low and manageable; 21 percent of patients experienced grade 1 or 2 nausea/vomiting and 29 percent experienced alopecia. Importantly, neither clinically relevant left ventricular ejection fraction (decrease heart function) nor clinical congestive heart failure was observed.

"The study results are promising and suggest the potential value of CAELYX in the management of metastatic breast cancer," said Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough Research Institute. "Further evaluation is indicated to
confirm that CAELYX is effective and safe for select metastatic breast cancer patients who are at increased cardiac risk."
The current approved dosage of CAELYX in metastatic breast cancer is 50 mg/m2, every 4 weeks. To manage certain adverse events, such as palmar-plantar erythrodysesthesia (PPE), the dose may be reduced.

Metastatic Breast Cancer
Metastatic breast cancer (MBC) is the most advanced stage of breast cancer (stage IV), in which cancer cells have spread past the breast and axillary (underarm) lymph nodes to other areas of the body where they continue to grow and multiply. Breast cancer has the potential to spread to almost any region of the body. The most common region breast cancer spreads to is bone, followed by lung and liver.

About CAELYX
CAELYX is a long-circulating pegylated liposomal formulation of doxorubicin hydrochloride, a widely used cytotoxic agent.
CAELYX is approved in the European Union (EU) as monotherapy for metastatic breast cancer in patients who are increased cardiac risk. CAELYX is also approved in the EU for the treatment of advanced ovarian cancer in women who have failed first-line, platinum-based therapy and for the treatment of AIDS-related Kaposi's s
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Appendicitis: Evolving Tools to Diagnose a Classic Disease
2. Non-Invasive Diagnostic Tests for Celiac Disease
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
8. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
9. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
10. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
11. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease